Lu Xifeng, Krop Manne, Batenburg Wendy W, Musterd-Bhaggoe Usha M, Garrelds Ingrid M, Danser A H Jan
Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands.
J Hypertens. 2014 Jun;32(6):1255-63. doi: 10.1097/HJH.0000000000000167.
VTP-27999 is a renin inhibitor with an IC50 that is comparable to that of aliskiren, but with a higher bioavailability. Unexpectedly, VTP-27999, unlike aliskiren, did not unfold renin's precursor, prorenin, and increased the affinity of the antibodies applied in renin immunoassays.
Here we verified to what degree these differences affect intracellular renin inhibitor accumulation in renin-synthesizing human mast cells (HMC-1), and (pro)renin's signaling via the (pro)renin receptor ((P)RR) in rat vascular smooth muscle cells. We also addressed the consequences of (P)RR knockdown by small-interfering (si) RNA on (pro)renin release. Finally, making use of FRET(Bodipy-FL)-labeled aliskiren, we studied, by subcellular fractionation, the cellular distribution pattern of this renin inhibitor.
VTP-27999 accumulated at higher levels in HMC-1 cells than aliskiren, allowing this inhibitor to block intracellular renin at approximately five-fold lower medium levels. Labeled aliskiren accumulated in mitochondria and lysosomes, and its distribution pattern was different from that of renin. Moreover, the intracellular accumulation of both inhibitors in nonrenin-synthesizing HEK293 cells was not different from that in HMC-1 cells, suggesting that it is renin synthesis-independent. VTP-27999, but not aliskiren, blocked renin's capacity to stimulate extracellular signal-regulated kinase 1/2 phosphorylation in vascular smooth muscle cells, whereas neither inhibitor interfered with prorenin-induced signaling. (P)RR knockdown greatly increased renin (and to a lesser degree, prorenin) release, without affecting the capacity of forskolin or cAMP to stimulate renin release.
VTP-27999 differs from aliskiren regarding its level of intracellular accumulation and its capacity to interfere with renin signaling via the (P)RR, and the (P)RR determines prorenin-renin conversion and constitutive (but not regulated) (pro)renin release.
VTP-27999是一种肾素抑制剂,其半数抑制浓度(IC50)与阿利吉仑相当,但生物利用度更高。出乎意料的是,与阿利吉仑不同,VTP-27999不会使肾素的前体——肾素原展开,并且会增加肾素免疫测定中所用抗体的亲和力。
在此,我们验证了这些差异在何种程度上影响肾素合成的人肥大细胞(HMC-1)中细胞内肾素抑制剂的积累,以及(原)肾素通过大鼠血管平滑肌细胞中的(原)肾素受体((P)RR)进行的信号传导。我们还探讨了通过小干扰(si)RNA敲低(P)RR对(原)肾素释放的影响。最后,利用荧光共振能量转移(FRET)(Bodipy-FL)标记的阿利吉仑,我们通过亚细胞分级分离研究了这种肾素抑制剂的细胞分布模式。
VTP-27999在HMC-1细胞中的积累水平高于阿利吉仑,使得该抑制剂能够在约低五倍的培养基水平下阻断细胞内肾素。标记的阿利吉仑在线粒体和溶酶体中积累,其分布模式与肾素不同。此外,两种抑制剂在不合成肾素的HEK293细胞中的细胞内积累与在HMC-1细胞中的情况并无差异,这表明其与肾素合成无关。VTP-27999而非阿利吉仑能够阻断肾素刺激血管平滑肌细胞中细胞外信号调节激酶1/2磷酸化的能力,而两种抑制剂均不干扰肾素原诱导的信号传导。敲低(P)RR会显著增加肾素(以及程度较轻的肾素原)的释放,而不影响福斯可林或环磷酸腺苷(cAMP)刺激肾素释放的能力。
VTP-27999在细胞内积累水平及其通过(P)RR干扰肾素信号传导的能力方面与阿利吉仑不同,并且(P)RR决定肾素原向肾素的转化以及组成性(而非调节性)(原)肾素释放。